...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs and aging >Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice
【24h】

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

机译：临床实践中多西紫杉醇治疗转移性阉割的前列腺癌患者的年龄相关的血液毒性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundOlder patients with metastatic castration-resistant prostate cancer (mCRPC) may be more prone to chemotherapy-induced hematological toxicity, but tailored docetaxel dosing guidelines in older patients are lacking because of conflicting data.ObjectiveThis study aims to evaluate the impact of older age on the incidence of hematological toxicity in patients with mCRPC treated with docetaxel in daily clinical practice.MethodsThis study included patients with mCRPC treated with docetaxel between January 2006 and January 2016 at the Netherlands Cancer Institute and Medical Center Slotervaart for whom dosing and hematological toxicity data were available from electronic patient records. We evaluated the impact of age on the incidence of grade 3 and 4 hematological toxicity.ResultsIn total, 175 patients treated with docetaxel were included in the analysis, with a median age of 67years (range 47-86). Baseline hematological laboratory values were not age related. After the first treatment cycle, hematological toxicity occurred significantly more frequently in the oldest age quartile (25%, p=0.02) than in the younger age quartiles (9%, 11%, and 7%, respectively, for age quartiles 1, 2, and 3).ConclusionThe risk of hematological toxicity was significantly higher in the oldest age quartile than in younger patients with mCRPC treated with docetaxel in daily clinical practice.
机译：背景技术患者患有转移性阉割前列腺癌（MCRPC）的患者可能更容易发生化疗诱导的血液毒性，但由于数据冲突，老年患者的量身定制的多西紫杉醇给药指南缺乏.Bobjectivethis研究旨在评估年龄较大的影响在日常临床实践中用多西紫杉醇治疗MCRPC患者的血液天动学毒性的发病率。一项研究包括在2006年1月至2016年1月和2016年1月在荷兰癌症研究所和医疗中心的MCRPC治疗的患者，其中可从中获得给药和血液学毒性数据。电子患者记录。我们评估了年龄对3年级和4级发病率的影响。分析中包含125名患者的175名患者，中位年龄为67岁（范围47-86）。基线血液学实验室值并不是年龄相关的。在第一次治疗循环之后，血液学毒性在最旧的年龄（25％，p = 0.02）中比较龄四分位数（分别为年龄四分位数1,2 3）。结论血液毒性的危险在最古老的年龄，比在日常临床实践中对多西紫杉醇治疗的患者患者患者患者患者显着高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号